Fortrea Holdings (FRA:K67) NonCurrent Deferred Liabilities : €126 Mil (As of Jun. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Fortrea Holdings NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Fortrea Holdings's non-current deferred liabilities for the quarter that ended in Jun. 2024 was €126 Mil.

Fortrea Holdings NonCurrent Deferred Liabilities Historical Data

The historical data trend for Fortrea Holdings's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fortrea Holdings NonCurrent Deferred Liabilities Chart

Fortrea Holdings Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

NonCurrent Deferred Liabilities

186.12

174.17

136.45

Fortrea Holdings Quarterly Data
	Dec20	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
NonCurrent Deferred Liabilities	Get a 7-Day Free Trial							170.02	160.88	136.45	138.64	126.44

Fortrea Holdings NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Fortrea Holdings's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Fortrea Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fortrea Holdings Inc (FRA:K67) » Definitions » NonCurrent Deferred Liabilities

Comparable Companies

Traded in Other Exchanges

FTRE:USA FTRE1:Mexico

Address

8 Moore Drive, Durham, NC, USA, 27709

Website

https://www.fortrea.com

Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after LabCorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.

Fortrea Holdings Headlines

No Headlines